Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting — Sponsor Intelligence | 21 EU Trials

Filter these 21 trials by condition, phase, country and more.

Open in Search →

21 Registered trials

8 Recruiting

13 Completed trials

15 Countries active

34 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase III: 7 Phase II: 11 Phase I/II: 3

Oversight events:

5 serious breaches 1 temporary halt 1 urgent safety measure across 5 trials

View oversight register →

100%

13 of 13 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Diffuse large B-cell lymphoma 3 Chronic lymphocytic leukaemia recurrent 1 Non-Hodgkin's lymphoma 1 Waldenstrom´s macroglobulinaemia recurrent 1 Myelodysplastic syndrome 1 Waldenstrom's macroglobulinaemia 1 Chronic lymphocytic leukaemia refractory 1 Primary myelofibrosis 1

Top IMPs

VENETOCLAX 7 EPCORITAMAB 2 IBRUTINIB 2 IVOSIDENIB 2 OBINUTUZUMAB 2 ATEZOLIZUMAB 1 AZACITIDINE 1 BLEXIMENIB 1 BLINATUMOMAB 1 BRENTUXIMAB VEDOTIN 1 CARFILZOMIB 1 DEXAMETHASONE 1

All trials

21 total

HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of ve… Pending

2025-524283-38-00 Phase III 1 country VENETOCLAX
HOVON 178 WM: Treatment of Waldenstrom’s macroglobulinemia with epcoritamab if the disease comes back during or after previous treatment Recruiting

2025-522295-91-00 Phase I/II 3 countries EPCORITAMAB
A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific… Recruiting

2025-522767-15-00 Phase III 14 countries BLEXIMENIB
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia … Recruiting

2024-512753-24-00 Phase III 14 countries IVOSIDENIB; VENETOCLAX
A study investigating the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML… Recruiting

2024-512733-32-00 Phase III 14 countries AZACITIDINE; REVUMENIB; VENETOCLAX
A phase 2 study of the effectiveness of golcadomide (CC-99282) for patients with large B-cell lymphoma in the brain Recruiting

2024-517051-12-00 Phase II 2 countries GOLCADOMIDE
HOVON 170 DLBCL: ANTICIPATE: Prevention of ANThracycline-Induced Cardiac dysfunction by dexrazoxane In PATients with diffusE large B-cell ly… Recruiting

2023-505377-32-00 Phase III 1 country DEXRAZOXANE
FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting

2023-508586-33-00 Phase III 1 country
HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in pa… Recruiting

2022-500305-40-00 Phase I/II 4 countries EPCORITAMAB; VENETOCLAX
HOVON 172 MF: Study on tasquinimod treatment in patients with myelofibrosis Ended

2024-511565-11-00 Phase I/II 2 countries TASQUINIMOD
First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in… Ended

2022-502808-72-00 Phase II 2 countries IBRUTINIB; OBINUTUZUMAB; VENETOCLAX
HOVON 164 HL: Tislelizumab plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma followed by Tislelizumab Consolidation… Ended

2022-502225-17-00 Phase II 3 countries TISLELIZUMAB
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Phase II 11 countries GILTERITINIB; MIDOSTAURIN
Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended

2022-502832-37-00 Phase III 12 countries ENASIDENIB MESILATE; IVOSIDENIB
Treatment with carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering Multi… Ended

2024-511334-12-00 Phase II 2 countries CARFILZOMIB; DEXAMETHASONE; LENALIDOMIDE
HOVON 151 DLBCL: A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diff… Ended

2022-501076-26-00 Phase II 2 countries ATEZOLIZUMAB
HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly d… Ended

2022-501038-48-00 Phase II 2 countries NIVOLUMAB
Transplant BRaVE NHL: Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse… Ended

2023-510556-22-00 Phase II 3 countries BRENTUXIMAB VEDOTIN
Blinatumomab added to prephase and consolidation therapy in precursor B-acute lymphoblastic leukemia in adults. Ended

2024-511050-44-00 Phase II 2 countries BLINATUMOMAB
A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who… Ended

2023-510557-42-00 Phase II 6 countries IBRUTINIB; VENETOCLAX
GIVE trial (Gazyvaro In combination with VEnetoclax in Elderly CLL) Ended

2024-511048-22-00 Phase II 1 country OBINUTUZUMAB; VENETOCLAX

Showing 1–21 of 21 trials

← All sponsors A–Z